Literature DB >> 11356588

How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment.

V Peralta1, M J Cuesta.   

Abstract

During the last two decades, much effort has been made to precisely characterize the symptom dimensions of schizophrenia. A number of dimensional models have been proposed, the most popular of which has been a three-dimensional model consisting of psychotic, negative and disorganizational symptoms. This model, however, has been criticized as too simplistic, and more complex models have been proposed, although to date there has been no consensus as to the number and nature of dimensions necessary to account for the whole range of schizophrenic symptoms. In the present paper, the authors review the main methodological issues which have led to the current confusion about the number of dimensions underlying schizophrenic psychopathology. Among the main issues influencing the delimitation of dimensions are: statistical procedures for determining the number of factors, phase of the illness, level of analysis of symptoms (i.e., symptoms or groups of symptoms), and measurement instrument used. Studies analyzing either a broad range of symptoms or particular symptoms at a finer level have produced a rather complex picture of schizophrenic dimensions. There is evidence supporting the existence of eight major dimensions of psychopathology: psychosis, disorganization, negative, mania, depression, excitement, catatonia and lack of insight. The dimensional structure of symptoms becomes even more complex if one considers that these big dimensions can be further divided into more elementary components. A hierarchical approach for organizing the complex dimensional structure of schizophrenic symptoms is proposed.

Entities:  

Mesh:

Year:  2001        PMID: 11356588     DOI: 10.1016/s0920-9964(00)00071-2

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  46 in total

1.  Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits.

Authors:  Joseph Ventura; April D Thames; Rachel C Wood; Lisa H Guzik; Gerhard S Hellemann
Journal:  Schizophr Res       Date:  2010-06-25       Impact factor: 4.939

Review 2.  Revisiting the diagnosis of schizophrenia: where have we been and where are we going?

Authors:  William R Keller; Bernard A Fischer; William T Carpenter
Journal:  CNS Neurosci Ther       Date:  2010-12-27       Impact factor: 5.243

3.  Meta-analysis of Positive and Negative Symptoms Reveals Schizophrenia Modifier Genes.

Authors:  Alexis C Edwards; Tim B Bigdeli; Anna R Docherty; Silviu Bacanu; Donghyung Lee; Teresa R de Candia; Arden Moscati; Dawn L Thiselton; Brion S Maher; Brandon K Wormley; Dermot Walsh; Francis A O'Neill; Kenneth S Kendler; Brien P Riley; Ayman H Fanous
Journal:  Schizophr Bull       Date:  2015-08-27       Impact factor: 9.306

4.  Co-morbid anxiety disorders in patients with schizophrenia in a tertiary institution in South East Nigeria: prevalence and correlates.

Authors:  Chinyere Aguocha; Kelechi Aguocha; Richard Uwakwe; Gabriel Onyeama
Journal:  Afr Health Sci       Date:  2015-03       Impact factor: 0.927

Review 5.  The structure of negative symptoms within schizophrenia: implications for assessment.

Authors:  Jack J Blanchard; Alex S Cohen
Journal:  Schizophr Bull       Date:  2005-10-27       Impact factor: 9.306

Review 6.  Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature.

Authors:  Ayman H Fanous; Kenneth S Kendler
Journal:  Curr Psychiatry Rep       Date:  2008-04       Impact factor: 5.285

7.  Catatonia in the DSM--shall we move or not?

Authors:  Stephan Heckers; Rajiv Tandon; Juan Bustillo
Journal:  Schizophr Bull       Date:  2009-11-23       Impact factor: 9.306

8.  Can genomics help usher schizophrenia into the age of RDoC and DSM-6?

Authors:  Ayman H Fanous
Journal:  Schizophr Bull       Date:  2015-05       Impact factor: 9.306

9.  Evidence for a role of the NOS1AP (CAPON) gene in schizophrenia and its clinical dimensions: an association study in a South American population isolate.

Authors:  Barbara Kremeyer; Jenny García; Hanna Kymäläinen; Naomi Wratten; Gabriel Restrepo; Carlos Palacio; Ana Lucía Miranda; Carlos López; Margarita Restrepo; Gabriel Bedoya; Linda M Brzustowicz; Jorge Ospina-Duque; María Patricia Arbeláez; Andrés Ruiz-Linares
Journal:  Hum Hered       Date:  2008-12-15       Impact factor: 0.444

10.  Smoking in schizophrenia: diagnostic specificity, symptom correlates, and illness severity.

Authors:  Roman Kotov; Lin T Guey; Evelyn J Bromet; Joseph E Schwartz
Journal:  Schizophr Bull       Date:  2008-06-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.